GlassScriptPhysician profile
Yamini Bear Rao
NPI 1932499761
$569.94
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $180 · 2021: $192 · 2022: $68.08.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $134.83 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $102.11 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $99.42 | 2019-2022 | |
| Cranial Technologies, INC | $56.97 | 2020-2022 | |
| Ultragenyx Pharmaceutical INC. | $40.93 | 2019-2020 | |
| Sanofi Pasteur INC. | $38.40 | 2019 | |
| Adlon Therapeutics L.P. | $17.34 | 2020 | |
| Shire North American Group INC | $17.23 | 2019 | |
| Kaleo, INC. | $16.75 | 2019 | |
| Oxford Immunotec USA INC | $15.42 | 2021 | |
| Merck Sharp & Dohme LLC | $15.27 | 2020 | |
| Supernus Pharmaceuticals, INC. | $15.27 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yamini Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.